They revealed that SLAMF2/CD48 was significantly upregulated in low-risk DLBCL patients whereas IL1RL, PSDM3, and RXFP3 were strongly elevated in high-risk DLBCL patients [46]. The gene discussed is CD48; the disease is diffuse large B-cell lymphoma.